Loading
A phase 2 trial in lung cancer, run by PrECOG, LLC., now recruiting.
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer is a phase 2, randomised interventional study registered as NCT07057791 by PrECOG, LLC., with a registry enrolment figure of 60 participants, started 2026-03-30 and due to reach its primary completion in 2027-12. Interventions recorded: Ivonescimab 10 mg/kg; Ivonescimab 20 mg/kg. Conditions listed: Extensive Stage Lung Small Cell Cancer. Primary outcome: Optimal Dose of Ivonescimab in Combination with Carboplatin and Etoposide - Overall Response Rate (ORR); Optimal Dose of Ivonescimab in Combination with Carboplatin and Etoposide - Grade 3-5 Treatment-Related Toxicity Rate. Lung eligibility wording from the registry: "* Patients must have pathologically confirmed Extensive Stage Small Cell Lung Cancer (ES-SCLC)". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.